2. Academic Validation
  3. Design of an amide N-glycoside derivative of β-glucogallin: a stable, potent, and specific inhibitor of aldose reductase

Design of an amide N-glycoside derivative of β-glucogallin: a stable, potent, and specific inhibitor of aldose reductase

  • J Med Chem. 2014 Jan 9;57(1):71-7. doi: 10.1021/jm401311d.
Linfeng Li 1,  Kun-Che Chang,  Yaming Zhou,  Biehuoy Shieh,  Jessica Ponder,  Adedoyin D Abraham,  Hadi Ali,  Anson Snow,  J Mark Petrash,  Daniel V LaBarbera
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States.
PMID: 24341381 DOI: 10.1021/jm401311d
Abstract

β-Glucogallin (BGG), a major component of the Emblica officinalis medicinal plant, is a potent and selective inhibitor of Aldose Reductase (AKR1B1). New linkages (ether/triazole/amide) were introduced via high yielding, efficient syntheses to replace the labile ester, and an original two-step (90%) preparation of BGG was developed. Inhibition of AKR1B1was assessed in vitro and using transgenic lens organ cultures, which identified the amide linked glucoside (BGA) as a stable, potent, and selective therapeutic lead toward the treatment of diabetic eye disease.

Figures
Products